Severe asthma and eligibility for biologics in a Brazilian cohort

Página do item simplificado
dc.contributor.authorMello, Luane Marques
dc.contributor.authorViana, Karynna P.
dc.contributor.authorSantos, Felipe Moraes dos
dc.contributor.authorSaturnino, Luciana T. M.
dc.contributor.authorKormann, Michelle L.
dc.contributor.authorLazaridis, Evelyn
dc.contributor.authorTorreão, Cinthia D.
dc.contributor.authorSoares, Claudia R.
dc.contributor.authorAbreu, Gabriela A.
dc.contributor.authorLima, Valmar Bião de
dc.contributor.authorPinheiro, Gabriela P.
dc.contributor.authorLima-Matos, Aline
dc.contributor.authorPonte, Eduardo Vieira
dc.contributor.authorMohan, Divya
dc.contributor.authorRiley, John H.
dc.contributor.authorCruz, Alvaro A.
dc.date.accessioned2024-10-25T18:30:16Z
dc.date.available2024-10-25T18:30:16Z
dc.date.issued2021
dc.description.abstractObjective: This study aims to describe the eligibility for biologic therapies for severe asthma (SA) in a cohort of patients attending the Program for Control of Asthma (ProAR) in Bahia, Brazil. Methods: Data from SA patients (18 years old) attending the ProAR, that were included in a case-control study conducted from 2013 to 2015, were used to reassess patients according to a modified ERS/ATS 2014 SA criteria. Patients were then classified according to the eligi- bility for SA biological therapy based on current prescription labels. Results: From 544 patients in the cohort, 531 (97.6%) were included and 172 (32.4%) were identified as SA patients according to the ERS/ATS 2014 modified criteria. Of these 172 patients, 69 (40.1%) were ineligible for any of the biologicals approved for asthma (omalizu- mab, mepolizumab, reslizumab and benralizumab), 60 (34.9%) patients were eligible for one of the biological therapies, and 10 (5.8%) patients were eligible for all biological therapies. Conclusions: More than half of patients with SA were eligible for biologic therapy in our study, but none of them received this form of treatment. Almost half of them were not eli- gible to any of the approved biologics, however. The variability and overlap in patients’ eli- gibility highlight the importance of evaluating each patient individually for a more personalized treatment approach. While there is a need to increase access for some of those eligible that may really need a biologic treatment, continuous efforts are required to develop alternatives to those who are not eligible.
dc.identifier.citationMarques Mello L, Viana KP, Moraes Dos Santos F, Saturnino LTM, Kormann ML, Lazaridis E, Torreão CD, Soares CR, Abreu GA, Lima VB, Pinheiro GP, Lima-Matos A, Ponte EV, Mohan D, Riley JH, Cruz AA. Severe asthma and eligibility for biologics in a Brazilian cohort. J Asthma. 2021 Jul;58(7):958-966. doi: 10.1080/02770903.2020.1748049.
dc.identifier.otherDOI: 10.1080/02770903.2020
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/537
dc.language.isoen
dc.publisherThe Journal of Asthma
dc.subjectBiological therapyen
dc.subjectbiomarkersen
dc.subjectpersonalized medicineen
dc.subjectanti IgEen
dc.subjectIL5en
dc.subjectIL5 receptoren
dc.titleSevere asthma and eligibility for biologics in a Brazilian cohort
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Mello LM et al_ J ASTHMA.pdf
Tamanho:
1.31 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente